36.07USD-0.44%Mkt Cap: 2.25B USDP/E: —Last update: 2026-05-26
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.25B USD
Enterprise Value2.22B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-229.97M USD
Revenue/Share—
Last Price36.07 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees130
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS50015M1099
Valuation
P/E (Trailing)—
P/E (Forward)-12.00
PEG—
EV/EBITDA-10.14
EV/Revenue—
P/S—
P/B20.69
EPS (TTM)-4.17
EPS (Forward)-3.12
52W Range
3.26074% of range47.84
52W High47.84 USD
52W Low3.260 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-146.12%
ROA-65.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-136.01M USD
CapEx (TTM)506.00K USD
FCF Margin—
FCF Yield-2.32%
Net Debt-113.54M USD
Net Debt/EBITDA0.52
Balance Sheet
Debt/Equity0.38
Current Ratio3.54
Quick Ratio3.42
Book Value/Sh1.808 USD
Cash/Share2.715 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)62.67 USD
Target Range56.00 USD – 80.00 USD
# Analysts6
Ownership
Shares Out.62.58M
Float39.28M
Insiders5.18%
Institutions93.93%
Short Interest
Short Ratio10.0d
Short % Float25.98%
Short % Out.16.38%
Shares Short10.25M
Short (prev mo.)9.85M
Technical
SMA 5037.68 (-4.3%)
SMA 20024.01 (+50.3%)
Beta2.32
S&P 52W Chg28.31%
Avg Vol (30d)648.66K
Avg Vol (10d)699.83K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—